Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
NCT ID: NCT05180097
Last Updated: 2026-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
84 participants
INTERVENTIONAL
2022-11-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
NCT05711628
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
NCT05922904
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
NCT05039073
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
NCT02572167
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
NCT04795869
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The standard of care for participants who are not in a study is salvage treatment with gemcitabine, dexamethasone and cisplatin (GDP). This treatment can reduce symptoms and may stop the lymphoma from growing for a few months or longer. This standard treatment is approved by Health Canada
We are doing this study because we want to find out if treatment with Pembrolizumab and Brentuximab vedotin is better or worse than the standard of care for this type of cancer, classical Hodgkin lymphoma. The standard of care is defined as care most people get for your cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GDP
Gemcitabine
1000mg/m2 IV, 30 mins D1, D8
Dexamethasone
40mg daily PO, D1-D4
Cisplatin
75mg/m2 IV, 1 hour, D1
Brentuximab vedotin + Pembrolizumab
Brentuximab vedotin
1.8 mg/kg IV, 30 mins, Q21 days
Pembrolizumab
200mg IV, 30 mins, Q 21 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gemcitabine
1000mg/m2 IV, 30 mins D1, D8
Dexamethasone
40mg daily PO, D1-D4
Cisplatin
75mg/m2 IV, 1 hour, D1
Brentuximab vedotin
1.8 mg/kg IV, 30 mins, Q21 days
Pembrolizumab
200mg IV, 30 mins, Q 21 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years of age or greater
* ECOG performance status 0-1
* Clinically and/or radiologically measurable disease as per the Lugano 2014 classification
* Life expectancy \> 90 days
* Absolute neutrophils ≥1.0 x 10\^9/L; Platelets ≥75 x 10\^9/L; Hemoglobin ≥80 g/L: Bilirubin ≤1.50 x UNL; AST and ALT ≤2.50 x UNL; Serum creatinine \<1.55 x UNL or Creatinine clearance ≥30 mL/min
* Participant is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires and/or health utility in either English or French
* Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form prior to enrollment in the trial to document their willingness to participate.
* Participants must be accessible for treatment and follow-up.
* In accordance with CCTG policy, protocol treatment is to begin within 2 working days of participant enrollment
* Women/men of childbearing potential must have agreed to use a highly effective contraceptive method during the study plus approximately 6 months after treatment completion
* All patients must have a tumour block from their primary diagnostic biopsy and relapse/refractory biopsy if available and the centre/pathologist must have agreed to release the block or recently cut slides for correlative analysis if the participant has consented. If the primary diagnostic biopsy is not accessible, the original pathology report should be submitted for review and a biopsy from the relapse/refractory disease must be submitted.
Exclusion Criteria
* History of peripheral neuropathy or dyspnea ≥ grade 2
* Participants with a history of other malignancies except: adequately treated non-melanoma skin cancer and superficial bladder cancer, curatively treated in-situ cancer of the cervix or breast, or localized excised prostate cancer, other solid tumours curatively treated with no evidence of disease for \> 3 years
* History of active CNS disease
* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (at doses more than 10 mg prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first and any dose of trial treatment
* Has active autoimmune disease that has required systemic treatment in the past 3 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs) or history of allogeneic transplantation. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
* Known history of human immunodeficiency virus (HIV), active Hepatitis C Virus infection, active Hepatitis B Virus infection or any uncontrolled active systemic infection requiring intravenous (IV) antibiotics. Participants that are Hepatitis B core antibody positive are eligible if they are HBV DNA negative and are concurrently treated with anti-viral therapy. Participants with a past history of hepatitis C who have eradicated the virus are eligible
* Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, angina, or myocardial infarction within 6 months of screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification
* Documented history of cerebral vascular event (stroke or transient ischemic attack)
* History of progressive multifocal leukoencephalopathy (PML).
* Any serious active disease or co-morbid medical condition, including psychiatric illness, judged by the local investigator to preclude safe administration of the planned protocol treatment or required follow-up
* Any other serious intercurrent illness, life-threatening condition, organ system dysfunction, or medical condition judged by the local investigator to compromise the subject's safety (for example): active, uncontrolled bacterial, fungal or viral infection; clinically significant cardiac dysfunction or cardiovascular disease
* Participants who have been vaccinated with live, attenuated vaccines within 4 weeks of enrollment
* Pregnant or lactating females, or women/men of childbearing potential not willing to use an adequate method of birth control for the duration of the study through 6 months after the last dose of trial treatment
* Participants are not eligible if they have had a prior infusion reaction to the study drugs or their components \> grade 2
* Participant has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
* Participant has had an allogenic tissue/solid organ transplant
* Concurrent or within the previous 4 weeks of randomization, treatment with other investigational drugs or anti-cancer therapy
* Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A one-week washout is permitted for palliative radiation (≤ 2 weeks of radiotherapy)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Pfizer
INDUSTRY
Australasian Leukaemia and Lymphoma Group
OTHER
Canadian Cancer Trials Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kerry Savage
Role: STUDY_CHAIR
BCCA-Vancouver Cancer Centre
John Kuruvilla
Role: STUDY_CHAIR
University Health Network, Princess Margaret Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Shoalhaven Cancer Care Centre
Nowra, New South Wales, Australia
Wollongong Hospital
Wollongong, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Austin Hospital
Heidelberg, Victoria, Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
BCCA - Vancouver
Vancouver, British Columbia, Canada
Dr. H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, Canada
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
London Health Sciences Centre Research Inc.
London, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
The Jewish General Hospital
Montreal, Quebec, Canada
The Research Institute of the McGill University
Montreal, Quebec, Canada
CIUSSS de l'Estrie - Centre hospitalier
Sherbrooke, Quebec, Canada
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Nicole WongDoo
Role: primary
Shrinivas Desai
Role: primary
Shrinivas Desai
Role: primary
Danielle Blunt
Role: primary
Eliza Hawkes
Role: primary
Katharine Lewis
Role: primary
Robert Puckrin
Role: primary
Kerry J. Savage
Role: primary
Jacqueline Costello
Role: primary
Mary-Margaret Keating
Role: primary
Amaris Balitsky
Role: primary
Joy Elise Mangel
Role: primary
Isabelle Bence-Bruckler
Role: primary
John Kuruvilla
Role: primary
Nathalie Johnson
Role: primary
Kelly Davison
Role: primary
Stephanie Desilets
Role: primary
Muhammad Salim
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HD11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.